0001096906-24-000493.txt : 20240318
0001096906-24-000493.hdr.sgml : 20240318
20240318180048
ACCESSION NUMBER: 0001096906-24-000493
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240314
FILED AS OF DATE: 20240318
DATE AS OF CHANGE: 20240318
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hansard Adam
CENTRAL INDEX KEY: 0001805556
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38898
FILM NUMBER: 24760400
MAIL ADDRESS:
STREET 1: C/O APPLIED THERAPEUTICS, INC.
STREET 2: 545 5TH AVENUE, SUITE 1400
CITY: NEW YORK
STATE: NY
ZIP: 10017
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Applied Therapeutics, Inc.
CENTRAL INDEX KEY: 0001697532
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 545 FIFTH AVENUE, SUITE 1400
CITY: NEW YORK
STATE: NY
ZIP: 10017
BUSINESS PHONE: 212-220-9226
MAIL ADDRESS:
STREET 1: 545 FIFTH AVENUE, SUITE 1400
CITY: NEW YORK
STATE: NY
ZIP: 10017
FORMER COMPANY:
FORMER CONFORMED NAME: Applied Therapeutics Inc.
DATE OF NAME CHANGE: 20170208
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-03-14
0
0001697532
Applied Therapeutics, Inc.
APLT
0001805556
Hansard Adam
C/O APPLIED THERAPEUTICS, INC.
545 FIFTH AVENUE, SUITE 1400
NEW YORK
NY
10017
0
1
0
0
Chief Commercial Officer
0
Common Stock
2024-03-14
4
S
0
48871.0000
5.3900
D
732919.0000
D
The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of compensatory Restricted Stock Units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.
Weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $5.37 to $5.795, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
/s/ Shoshana Shendelman, Attorney-in-Fact
2024-03-18